Von Willebrand disease type 2N

Von Willebrand disease type 2N (VWD type 2N), also known as VWD Normandy, is a rare inherited bleeding disorder caused by mutations in the VWF gene that specifically impair the ability of von Willebrand factor (VWF) to bind coagulation factor VIII (FVIII). Because VWF normally protects FVIII from premature degradation in the bloodstream, patients with type 2N have markedly reduced FVIII levels while VWF antigen levels may appear normal or near-normal. This can lead to a clinical presentation that closely mimics mild hemophilia A, which is why VWD type 2N is sometimes called 'autosomal hemophilia.' The disease primarily affects the blood coagulation system. Key symptoms include excessive bleeding after surgery or dental procedures, easy bruising, prolonged bleeding from wounds, menorrhagia (heavy menstrual bleeding) in women, and in more severe cases, joint bleeding or mucosal bleeding such as nosebleeds. Symptoms can range from mild to moderate in severity. Because FVIII levels are reduced rather than VWF activity, standard VWD screening tests such as ristocetin cofactor activity may be normal, making diagnosis challenging. A specific VWF:FVIII binding assay is required to confirm the diagnosis. Treatment of VWD type 2N centers on replacing the deficient functional VWF to stabilize endogenous FVIII. VWF-containing FVIII concentrates (such as plasma-derived VWF/FVIII concentrates like Humate-P or Wilate) are the mainstay of therapy for bleeding episodes and surgical prophylaxis. Desmopressin (DDAVP) may provide a transient increase in FVIII levels in some patients but is often insufficient because the released VWF still has impaired FVIII binding capacity, leading to rapid clearance of FVIII. Antifibrinolytic agents such as tranexamic acid may be used as adjunctive therapy, particularly for mucosal bleeding. Genetic counseling is recommended for affected families.

Common questions about Von Willebrand disease type 2N